RGLS - Margin dodolan resik Regulus Therapeutics Inc.

Regulus Therapeutics Inc. - logo grafis emiten RGLS

Regulus Therapeutics (RGLS) currently generates no revenue, relying instead on high-risk development and the regular issuance of new shares. The aggregate net margin clearly demonstrates this efficiency momentum, with the value stabilizing at 0.00. A team of elite geneticists is developing miRNA therapy, while anticipation of the Phase 2 trial results for the treatment of polycystic kidney disease serves as the primary growth driver.

Margin bathi resik Regulus (RGLS): kanggo periode 04.07.2022 - 05.07.2025

RGLS (Regulus Therapeutics): rincian analitis lan laporan miturut indikator

- nilai pasar lan prakiraan target analis:
Pambiji fundamental perusahaan:Regulus Therapeutics, Inc. - RGLS
Produk dadi Regulus

Regulus Therapeutics (RGLS) is actively developing innovative RNA therapies to combat polycystic kidney disease. High clinical trial costs make financial results extremely sensitive to operating expenses. This metric determines the percentage of revenue remaining after deducting all business costs. It allows for the identification of one-time efficiency spikes and profit squeeze risks. By analyzing the net profitability chart, an investor assesses the asset's real ability to generate free income.

Pesaing Regulus Therapeutics (RGLS)

TEM: Margin dodolan resik|Tingkat bathi miturut bathi resik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Margin dodolan resik|Repligen Inc. - Margin bathi resik|Margin dodolan resik RNA|CRSP - Margin resik|GeneDx - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik RARE|Beam Tx - Margin dodolan resik|SRPT - Margin dodolan resik|TWST (Twist Bio) - Rentabilitas dodolan miturut bathi resik|Rentabilitas dodolan resik TXG|Rentabilitas dodolan miturut bathi resik NTLA|Stoke Therapeutics Inc (STOK) - Margin dodolan perusahaan|Margin dodolan resik BLFS|Margin resik WVE (Wave Life Sciences Corp)|Margin resik Maze Therapeutics MAZE|Tingkat bathi resik SION|PRME - Margin resik|Margin dodolan perusahaan Taysha TSHA|QURE: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MeiraGTx PLC|RGNX (REGENXBIO Inc) - Margin dodolan resik|solidbio.com (SLDB) - Margin dodolan perusahaan|Margin resik Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Rentabilitas dodolan resik|Benitec Biopharma - Rentabilitas dodolan miturut bathi resik|DSGN: Rentabilitas dodolan resik|RCKT: Rentabilitas dodolan miturut bathi resik|FDMT - Margin dodolan resik|LXEO: Margin dodolan resik|Korro Bio Inc. - Tingkat bathi resik|EDIT (editasmedicine.com) - Margin dodolan resik|Margin resik SLN|Margin resik ProQR Therapeutics NV (PRQR)|Codexis - Rentabilitas dodolan resik|Margin resik Sangamo SGMO|NAUT: Rentabilitas dodolan resik|MGX: Rentabilitas dodolan miturut bathi resik|Margin resik Precision BioSciences|GBIO (generationbio.com) - Rentabilitas dodolan miturut bathi resik|Margin resik boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Margin dodolan resik|Rentabilitas dodolan resik IMNN (Imunon, Inc.)|Margin dodolan resik PHIO|MBIO - Margin resik|Margin dodolan resik RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Margin resik|Applied DNA - Margin dodolan resik|Margin resik Bluebird Bio|ImmunoPrecise (IPA) - Margin resik|Margin bathi resik OMGA (Omega)|Margin resik Singular Genomics Systems|SYRS: Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik TBIO (Telesis Bio Inc.)|Margin dodolan resik TRACON Pharmaceuticals Inc. (TCON)|Margin resik Unity Bio UBX